Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

BACKGROUND: Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor mutational burden (TMB) also being explored with pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Kellie N., Llosa, Nicolas J., Cottrell, Tricia R., Siegel, Nicholas, Fan, Hongni, Suri, Prerna, Chan, Hok Yee, Guo, Haidan, Oke, Teniola, Awan, Anas H., Verde, Franco, Danilova, Ludmila, Anagnostou, Valsamo, Tam, Ada J., Luber, Brandon S., Bartlett, Bjarne R., Aulakh, Laveet K., Sidhom, John-William, Zhu, Qingfeng, Sears, Cynthia L., Cope, Leslie, Sharfman, William H., Thompson, Elizabeth D., Riemer, Joanne, Marrone, Kristen A., Naidoo, Jarushka, Velculescu, Victor E., Forde, Patrick M., Vogelstein, Bert, Kinzler, Kenneth W., Papadopoulos, Nickolas, Durham, Jennifer N., Wang, Hao, Le, Dung T., Justesen, Sune, Taube, Janis M., Diaz, Luis A., Brahmer, Julie R., Pardoll, Drew M., Anders, Robert A., Housseau, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371497/
https://www.ncbi.nlm.nih.gov/pubmed/30744692
http://dx.doi.org/10.1186/s40425-018-0492-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371497/
https://www.ncbi.nlm.nih.gov/pubmed/30744692
http://dx.doi.org/10.1186/s40425-018-0492-x

Ejemplares similares